Association between Phosphorylated AMP-Activated Protein Kinase and MAPK3/1 Expression and Prognosis for Patients with Gastric Cancer

Objectives: Phosphorylated AMP-activated protein kinase (pAMPK) plays a central role in cellular metabolic sensing and energy balance homeostasis, and interacts with various pathways [e.g., TP53, mTOR, NUAK2 (sucrose nonfermenting-like kinase), MAPK3/1 (ERK) and PDK]. Therefore, the present study analyzed the expression of pAMPK, NUAK2, MAPK3/1 and PDK-1 and their effect on the survival of patients with resected gastric cancer. Methods: A total of 621 patients with gastric adenocarcinoma surgically resected with curative intent were enrolled in the study. Immunohistochemical staining for pAMPK, NUAK2, MAPK3/1 and PDK-1 was performed using tissue microarrays of surgical specimens of gastric cancer tissue. Results: Positive pAMPK, NUAK2, MAPK3/1 and PDK-1 expression was observed in 379 (61.0%), 257 (41.4%), 327 (52.7%) and 67 (10.8%) cases, respectively. Multivariate survival analysis showed a significantly better survival for the patients with positive pAMPK or MAPK3/1 expression than for the patients with a negative expression [pAMPK: disease-free survival (DFS), hazard ratio (HR) = 0.750, 95% confidence interval (CI) = 0.568-0.970, p = 0.030; MAPK3/1: DFS, HR = 0.692, 95% CI = 0.720-0.974, p = 0.021), while NUAK2 or PDK-1 expression had no effect on survival. Conclusion: pAMPK or MAPK3/1 expression was found to be an independent prognostic marker for patients with resected gastric cancer.

[1]  J. Ha,et al.  AMP-activated protein kinase modulators: a patent review (2006 – 2010) , 2011, Expert opinion on therapeutic patents.

[2]  D. Richardson,et al.  AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. , 2011, Biochemical Society transactions.

[3]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[4]  G. Merlino,et al.  Uncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAFV600E , 2009, PloS one.

[5]  S. Lippman,et al.  The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[7]  V. Steele,et al.  Energy Homeostasis and Cancer Prevention: The AMP-Activated Protein Kinase , 2009, Cancer Prevention Research.

[8]  I. Kang,et al.  AMP-activated Protein Kinase Antagonizes Pro-apoptotic Extracellular Signal-regulated Kinase Activation by Inducing Dual-specificity Protein Phosphatases in Response to Glucose Deprivation in HCT116 Carcinoma* , 2010, The Journal of Biological Chemistry.

[9]  Philip R Quinlan,et al.  Histological evaluation of AMPK signalling in primary breast cancer , 2009, BMC Cancer.

[10]  Nahum Sonenberg,et al.  The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase , 2008, Cancer Prevention Research.

[11]  H. Clevers,et al.  Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer , 2007, Oncogene.

[12]  D. Carling,et al.  Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. , 2002, Diabetes.

[13]  H. Ngan,et al.  Inhibition of Cervical Cancer Cell Growth through Activation of Upstream Kinases of AMP-Activated Protein Kinase , 2009, Tumor Biology.

[14]  R. Shaw,et al.  The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.

[15]  A. Fornace,et al.  AMP-activated protein kinase promotes human prostate cancer cell growth and survival , 2009, Molecular Cancer Therapeutics.

[16]  O. Fiehn,et al.  Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. , 2011, Oncology reports.

[17]  M. Loda,et al.  Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer , 2010, British Journal of Cancer.

[18]  Ming Tan,et al.  Emerging metabolic targets in cancer therapy. , 2011, Frontiers in bioscience.

[19]  K. Dahlman-Wright,et al.  Metabolic diseases and cancer risk , 2012, Current opinion in oncology.

[20]  K. Inoki,et al.  Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. , 2009, Human molecular genetics.

[21]  J. Ha,et al.  Screening methods for AMP-activated protein kinase modulators: a patent review , 2015, Expert opinion on therapeutic patents.

[22]  Takafumi Ando,et al.  Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: Data from a single institute over 30 years , 2007, Journal of gastroenterology and hepatology.

[23]  Li Zhang,et al.  Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma , 2006, Clinical Cancer Research.

[24]  T. Löning,et al.  Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer , 2005, British Journal of Cancer.

[25]  J. Chen,et al.  Multiple signal pathways in obesity‐associated cancer , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[26]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[27]  K. Guan,et al.  AMP‐activated protein kinase and cancer , 2009, Acta physiologica.